Extended Data Table 2 GO30140 demographic summary in BEP and ITT populations

From: Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma

  1. Data presented as n (%) unless otherwise indicated. A, Arm A; AFP, α-fetoprotein; BEP, biomarker-evaluable population; F, female; F1, Arm F1; F2, Arm F2; ITT, intention-to-treat population; M, male; max, maximum; min, minimum.
Back to article page